CN101313064A - 基因扩增方法 - Google Patents
基因扩增方法 Download PDFInfo
- Publication number
- CN101313064A CN101313064A CNA200680043921XA CN200680043921A CN101313064A CN 101313064 A CN101313064 A CN 101313064A CN A200680043921X A CNA200680043921X A CN A200680043921XA CN 200680043921 A CN200680043921 A CN 200680043921A CN 101313064 A CN101313064 A CN 101313064A
- Authority
- CN
- China
- Prior art keywords
- double
- target sequence
- site
- record
- stranded dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 27
- 230000004544 DNA amplification Effects 0.000 title claims abstract description 12
- 108020004414 DNA Proteins 0.000 claims abstract description 108
- 102000053602 DNA Human genes 0.000 claims abstract description 74
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 63
- 108010052160 Site-specific recombinase Proteins 0.000 claims abstract description 54
- 230000003321 amplification Effects 0.000 claims abstract description 43
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 43
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 14
- 239000012634 fragment Substances 0.000 claims description 79
- 210000000349 chromosome Anatomy 0.000 claims description 29
- 108020005091 Replication Origin Proteins 0.000 claims description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 8
- 108010051219 Cre recombinase Proteins 0.000 claims description 7
- 230000006801 homologous recombination Effects 0.000 claims description 7
- 238000002744 homologous recombination Methods 0.000 claims description 7
- 239000013612 plasmid Substances 0.000 claims description 7
- 108010046276 FLP recombinase Proteins 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 5
- 239000013598 vector Substances 0.000 claims description 4
- 108010091086 Recombinases Proteins 0.000 claims description 2
- 102000018120 Recombinases Human genes 0.000 claims description 2
- 230000008676 import Effects 0.000 claims 2
- 230000010076 replication Effects 0.000 abstract description 54
- 230000006798 recombination Effects 0.000 abstract description 30
- 238000005215 recombination Methods 0.000 abstract description 30
- 241001465754 Metazoa Species 0.000 abstract description 3
- 230000002194 synthesizing effect Effects 0.000 abstract description 2
- 230000001960 triggered effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 51
- 101150036876 cre gene Proteins 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 18
- 102000004190 Enzymes Human genes 0.000 description 14
- 108090000790 Enzymes Proteins 0.000 description 14
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 12
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 239000003550 marker Substances 0.000 description 10
- 210000004102 animal cell Anatomy 0.000 description 9
- 238000002105 Southern blotting Methods 0.000 description 8
- 238000012216 screening Methods 0.000 description 8
- 230000022131 cell cycle Effects 0.000 description 7
- 239000013611 chromosomal DNA Substances 0.000 description 7
- 238000003776 cleavage reaction Methods 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 230000007017 scission Effects 0.000 description 7
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 6
- 108010022394 Threonine synthase Proteins 0.000 description 6
- 238000005520 cutting process Methods 0.000 description 6
- 102000004419 dihydrofolate reductase Human genes 0.000 description 6
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 6
- 102000005396 glutamine synthetase Human genes 0.000 description 6
- 108020002326 glutamine synthetase Proteins 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 108010061833 Integrases Proteins 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 108010084455 Zeocin Proteins 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 5
- 238000003906 pulsed field gel electrophoresis Methods 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 210000003411 telomere Anatomy 0.000 description 5
- 102000055501 telomere Human genes 0.000 description 5
- 108091035539 telomere Proteins 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 4
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 4
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 4
- 102000055025 Adenosine deaminases Human genes 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 4
- 108010070255 Aspartate-ammonia ligase Proteins 0.000 description 4
- 102100034343 Integrase Human genes 0.000 description 4
- 102000003792 Metallothionein Human genes 0.000 description 4
- 108090000157 Metallothionein Proteins 0.000 description 4
- 229930193140 Neomycin Natural products 0.000 description 4
- 102000052812 Ornithine decarboxylases Human genes 0.000 description 4
- 108700005126 Ornithine decarboxylases Proteins 0.000 description 4
- 241000235343 Saccharomycetales Species 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 229930189065 blasticidin Natural products 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 229960004927 neomycin Drugs 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 210000005253 yeast cell Anatomy 0.000 description 4
- 108700010070 Codon Usage Proteins 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 230000018199 S phase Effects 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000005757 colony formation Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 229930182830 galactose Natural products 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 230000002250 progressing effect Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 238000005096 rolling process Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000001360 synchronised effect Effects 0.000 description 3
- 230000014621 translational initiation Effects 0.000 description 3
- 102000006267 AMP Deaminase Human genes 0.000 description 2
- 102100032123 AMP deaminase 1 Human genes 0.000 description 2
- 108700016228 AMP deaminases Proteins 0.000 description 2
- 102000030907 Aspartate Carbamoyltransferase Human genes 0.000 description 2
- 108020004638 Circular DNA Proteins 0.000 description 2
- 101000797456 Dictyostelium discoideum AMP deaminase Proteins 0.000 description 2
- 108091000126 Dihydroorotase Proteins 0.000 description 2
- 101000775844 Homo sapiens AMP deaminase 1 Proteins 0.000 description 2
- 101000607560 Homo sapiens Ubiquitin-conjugating enzyme E2 variant 3 Proteins 0.000 description 2
- 101150056265 LYS5 gene Proteins 0.000 description 2
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 101150006914 TRP1 gene Proteins 0.000 description 2
- 102100039936 Ubiquitin-conjugating enzyme E2 variant 3 Human genes 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000002230 centromere Anatomy 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 1
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 229930195573 Amycin Natural products 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 241000702191 Escherichia virus P1 Species 0.000 description 1
- 101000718476 Homo sapiens L-aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferase Proteins 0.000 description 1
- 102100026384 L-aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferase Human genes 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102000008297 Nuclear Matrix-Associated Proteins Human genes 0.000 description 1
- 108010035916 Nuclear Matrix-Associated Proteins Proteins 0.000 description 1
- 102100037214 Orotidine 5'-phosphate decarboxylase Human genes 0.000 description 1
- 108010055012 Orotidine-5'-phosphate decarboxylase Proteins 0.000 description 1
- 108091081548 Palindromic sequence Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000001726 chromosome structure Anatomy 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 108700024542 myc Genes Proteins 0.000 description 1
- 210000000299 nuclear matrix Anatomy 0.000 description 1
- 101150095319 orc1 gene Proteins 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6867—Replicase-based amplification, e.g. using Q-beta replicase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (19)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP338119/2005 | 2005-11-24 | ||
JP2005338119 | 2005-11-24 | ||
PCT/JP2006/314168 WO2007060764A1 (ja) | 2005-11-24 | 2006-07-18 | 遺伝子増幅法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101313064A true CN101313064A (zh) | 2008-11-26 |
CN101313064B CN101313064B (zh) | 2012-11-28 |
Family
ID=38067002
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200680043921XA Expired - Fee Related CN101313064B (zh) | 2005-11-24 | 2006-07-18 | 基因扩增方法 |
Country Status (5)
Country | Link |
---|---|
US (3) | US20090148895A1 (zh) |
EP (1) | EP1967585B1 (zh) |
JP (1) | JP4821012B2 (zh) |
CN (1) | CN101313064B (zh) |
WO (1) | WO2007060764A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10448621B2 (en) | 2013-03-13 | 2019-10-22 | Regeneron Pharmaceuticals, Inc. | Rodent embryonic stem cell with conditional ACVR1 mutant alleles |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4821012B2 (ja) | 2005-11-24 | 2011-11-24 | 大学共同利用機関法人自然科学研究機構 | 遺伝子増幅法 |
US8921072B2 (en) | 2008-09-02 | 2014-12-30 | General Electric Compnay | Methods to generate DNA mini-circles |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK153992D0 (da) * | 1992-12-22 | 1992-12-22 | Novo Nordisk As | Metode |
EP1112385A1 (en) * | 1998-09-15 | 2001-07-04 | Yale University | Artificial long terminal repeat vectors |
AU2002219841A1 (en) * | 2000-11-16 | 2002-05-27 | Cornell Research Foundation Inc. | Vectors for conditional gene inactivation |
WO2005001087A2 (en) * | 2003-06-11 | 2005-01-06 | Regeneron Pharmaceuticals, Inc. | Methods of modifying genes in eukaryotic cells |
CA2546502A1 (en) * | 2003-11-25 | 2005-07-07 | Japan Science And Technology Agency | A method for gene amplification |
JP4821012B2 (ja) | 2005-11-24 | 2011-11-24 | 大学共同利用機関法人自然科学研究機構 | 遺伝子増幅法 |
-
2006
- 2006-07-18 JP JP2007546357A patent/JP4821012B2/ja not_active Expired - Fee Related
- 2006-07-18 EP EP06768267A patent/EP1967585B1/en not_active Not-in-force
- 2006-07-18 CN CN200680043921XA patent/CN101313064B/zh not_active Expired - Fee Related
- 2006-07-18 US US12/085,476 patent/US20090148895A1/en not_active Abandoned
- 2006-07-18 WO PCT/JP2006/314168 patent/WO2007060764A1/ja active Application Filing
-
2013
- 2013-05-09 US US13/890,533 patent/US9464307B2/en not_active Expired - Fee Related
-
2016
- 2016-09-09 US US15/261,274 patent/US20170037428A1/en not_active Abandoned
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10448621B2 (en) | 2013-03-13 | 2019-10-22 | Regeneron Pharmaceuticals, Inc. | Rodent embryonic stem cell with conditional ACVR1 mutant alleles |
US10470444B2 (en) | 2013-03-13 | 2019-11-12 | Regeneron Pharmaceuticals, Inc. | Method for making a genetically modified mouse with an inducible ACVR1 mutation that causes ectopic bone formation |
US10531648B2 (en) | 2013-03-13 | 2020-01-14 | Regeneron Pharmaceuticals, Inc. | Conditional rodent Acvr1 mutant gene |
USRE49121E1 (en) | 2013-03-13 | 2022-07-05 | Regeneron Pharmaceuticals, Inc. | Genetically modified mouse with an inducible ACVR1 gene with a mutant R206H exon 5 that has ectopic bone formation |
Also Published As
Publication number | Publication date |
---|---|
JPWO2007060764A1 (ja) | 2009-05-07 |
US20130266988A1 (en) | 2013-10-10 |
US9464307B2 (en) | 2016-10-11 |
WO2007060764A1 (ja) | 2007-05-31 |
CN101313064B (zh) | 2012-11-28 |
JP4821012B2 (ja) | 2011-11-24 |
US20090148895A1 (en) | 2009-06-11 |
US20170037428A1 (en) | 2017-02-09 |
EP1967585B1 (en) | 2011-12-28 |
EP1967585A1 (en) | 2008-09-10 |
EP1967585A4 (en) | 2010-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2020201190B2 (en) | Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency | |
KR101692103B1 (ko) | 합성 피타아제 변이체 | |
KR20220066914A (ko) | 부정맥 유발성 우심실 심근병증의 유전자 요법 조성물 및 치료 | |
CN110117551B (zh) | 生产瓦伦西亚烯的酿酒酵母工程菌及其构建方法与应用 | |
KR20140009516A (ko) | 합성 피타아제 변이체 | |
KR20160060659A (ko) | Hiv 감염증의 rna-유도 치료를 위한 방법 및 조성물 | |
KR20230159471A (ko) | 우심실 부정맥성 심근병증의 유전자 치료 조성물 및 치료 | |
CN114410687B (zh) | 一种适用地中海贫血症和镰刀形贫血基因治疗的慢病毒载体 | |
CN111269888A (zh) | 一种adipsin基因修饰的脂肪干细胞、制备方法及其应用 | |
CN101313064A (zh) | 基因扩增方法 | |
CN116987693A (zh) | 一种优化的CRISPR/SpCas12f1系统、工程化向导RNA及其应用 | |
CN102352371B (zh) | 一种pC系列质粒及其构建方法和应用 | |
KR20240131976A (ko) | 뇌 조직으로 유전자를 전달하기 위한 조성물 및 이의 용도 | |
CN112301058B (zh) | 一种重组腺相关病毒载体及其制备方法与应用 | |
CN109097362B (zh) | 操纵子、其载体及其应用 | |
CN108939064B (zh) | 基于重组减毒绵羊李斯特菌的宫颈癌治疗性疫苗 | |
CN114317610B (zh) | 一种适用于帕金森疾病基因治疗的慢病毒载体 | |
CN112301057B (zh) | 一种重组腺相关病毒载体及其制备方法与应用 | |
US6548301B2 (en) | Retroviral gene transfer vectors | |
CN109735558B (zh) | 一种重组car19-il24基因、慢病毒载体、car19-il24-t细胞及应用 | |
CN115161294A (zh) | 新城疫疫苗株及其构建方法、禽类免疫识别方法、应用 | |
CN113880957A (zh) | 一种链球菌溶血素o融合蛋白 | |
US20190030128A1 (en) | Compositions and Methods for Treatment of Central Nervous System Diseases | |
CN114277190A (zh) | 一种hiPSC中外源基因残留检测用特异性DNA片段、引物、试剂盒和检测方法 | |
CN114686521A (zh) | 一种重组腺相关病毒载体及其制备方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: TAKAAKI WATANABE Effective date: 20150713 Owner name: TAKASHI HORIUCHI Free format text: FORMER OWNER: INTER-UNIVERSITY RESEARCH INSTITUTE CORPORATION NATIONAL INSTITUTES OF NATURAL SCIENCES Effective date: 20150713 Owner name: GENODIVE PHARMA INC. Free format text: FORMER OWNER: TAKASHI HORIUCHI Effective date: 20150713 Owner name: TAKAAKI WATANABE Effective date: 20150713 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150713 Address after: Yokohama City, Kanagawa Prefecture, Japan Patentee after: GENODIVE PHARMA Inc. Address before: The city of Okazaki, Aichi Prefecture Patentee before: Horiuchi Takashi Patentee before: Watake Takaaki Effective date of registration: 20150713 Address after: The city of Okazaki, Aichi Prefecture Patentee after: Horiuchi Takashi Patentee after: Watake Takaaki Address before: Tokyo, Japan Patentee before: INTER University RESEARCH INSTITUTE CORPORATION NATIONAL INSTITUTES OF NATURAL SCIENCES |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20121128 Termination date: 20190718 |